These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24249742)

  • 21. Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.
    Bestas B; Moreno PM; Blomberg KE; Mohammad DK; Saleh AF; Sutlu T; Nordin JZ; Guterstam P; Gustafsson MO; Kharazi S; Piątosa B; Roberts TC; Behlke MA; Wood MJ; Gait MJ; Lundin KE; El Andaloussi S; Månsson R; Berglöf A; Wengel J; Smith CI
    J Clin Invest; 2014 Sep; 124(9):4067-81. PubMed ID: 25105368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
    N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Primary immunodeficiencies are a topical problem of modern medicine].
    Troitskaya EV; Sofronova LV; Tsvetkova TY
    Ter Arkh; 2014; 86(11):12-5. PubMed ID: 25715480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [X-linked agammaglobulinemia: experience in a Portuguese hospital].
    Fernandes A; Guedes M; Vasconcelos J; Neves E; Fernandes S; Marques L
    An Pediatr (Barc); 2015 Mar; 82(3):166-71. PubMed ID: 25443324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
    Aalipour A; Advani RH
    Ther Adv Hematol; 2014 Aug; 5(4):121-33. PubMed ID: 25360238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects.
    Ghosh S; Bienemann K; Boztug K; Borkhardt A
    J Clin Immunol; 2014 Nov; 34(8):892-9. PubMed ID: 25339095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.
    Broides A; Hadad N; Levy J; Levy R
    J Clin Immunol; 2014 Jul; 34(5):555-60. PubMed ID: 24771458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Bruton's tyrosine kinase in B cell malignancies.
    Hendriks RW; Yuvaraj S; Kil LP
    Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.
    Wang J; Lau KY; Jung J; Ravindran P; Barrat FJ
    Eur J Immunol; 2014 Apr; 44(4):1130-6. PubMed ID: 24375473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X; Piasecka-Stryczynska K; Kuhle J; Benkert P; Arnold DL; Weber MS; Seitzinger A; Guehring H; Shaw J; Tomic D; Hyvert Y; Harlow DE; Dyroff M; Wolinsky JS
    Mult Scler; 2024 Apr; 30(4-5):558-570. PubMed ID: 38436271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
    Kuter DJ; Mayer J; Efraim M; Bogdanov LH; Baker R; Kaplan Z; Garg M; Trněný M; Choi PY; Jansen AJG; McDonald V; Bird R; Gumulec J; Kostal M; Gernsheimer T; Ghanima W; Daak A; Cooper N
    Blood Adv; 2024 Apr; 8(7):1715-1724. PubMed ID: 38386978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review on Role of Inflammation in Coronavirus Disease.
    Lotfi A; Hajian P; Abbasi L; Gargari MK; Fard NNG; Naderi D
    Endocr Metab Immune Disord Drug Targets; 2024; 24(13):1488-1505. PubMed ID: 38303532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical advances in immunotherapy for immune-mediated glomerular diseases.
    Tang B; Yang X
    Clin Exp Med; 2023 Dec; 23(8):4091-4105. PubMed ID: 37889398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilzabrutinib
    Kuter DJ; Bussel JB; Ghanima W; Cooper N; Gernsheimer T; Lambert MP; Liebman HA; Tarantino MD; Lee M; Guo H; Daak A
    Ther Adv Hematol; 2023; 14():20406207231205431. PubMed ID: 37869360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutics and future directions for refractory immune thrombocytopenia.
    Al-Samkari H; Neufeld EJ
    Br J Haematol; 2023 Oct; 203(1):65-78. PubMed ID: 37735554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
    Ucpinar S; Smith PF; Long L; Li F; Yan H; Wadhwa J; Chu KA; Shu J; Nunn P; Li M
    Clin Transl Sci; 2023 Jul; 16(7):1210-1219. PubMed ID: 37060187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.
    Mok CC
    Drugs; 2023 Apr; 83(6):479-496. PubMed ID: 36972009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.